Scientists have developed a new maternal blood test capable of detecting thousands of serious genetic conditions in a developing fetus. This non-invasive technique, called NIFS, uses advanced sequencing to analyze fetal DNA fragments in the mother's blood, potentially reducing the need for invasive procedures like amniocentesis.
This new blood test could revolutionize prenatal diagnostics by offering a comprehensive, non-invasive method to screen for thousands of genetic conditions, potentially improving early diagnosis and management of fetal health while reducing risks associated with invasive procedures.
Scientists have developed a new maternal blood test, termed non-invasive foetal sequencing (NIFS), capable of detecting thousands of serious genetic conditions in a developing fetus. This breakthrough, to be presented at the European Society for Human Genetics conference, analyzes tiny fragments of fetal DNA circulating in the mother's bloodstream, potentially offering a safer and equally accurate alternative to invasive diagnostic methods like amniocentesis or chorionic villus sampling (CVS).
Dr. Christopher Whelan, a senior computational scientist at the Broad Institute of MIT and Harvard University, stated that the test can identify a vast number of genetic conditions, including those on major newborn sequencing and fetal anomaly panels. Examples of detected conditions include Noonan syndrome, Charge syndrome, Stickler syndrome, and achondroplasia, among many other rare disorders where early diagnosis could influence pregnancy, delivery, or newborn care.
While non-invasive blood tests for conditions like Down's syndrome already exist, this new technique significantly expands the scope to nearly all genetic conditions screened at birth. Whelan envisions NIFS as a frontline test, especially when ultrasound anomalies are detected, addressing the common refusal of invasive methods due to risks such as miscarriage, stress, access issues, and cost.
In validation studies involving 565 pregnancies, NIFS demonstrated high accuracy, identifying 95-99% of genetic variants found by invasive procedures and over 97% of clinically relevant variants. Researchers sequenced fetal DNA across nearly 23,000 genes. Professor Alexandre Reymond of the University of Lausanne described the genome sequencing of a fetus without direct sampling as a "tour de force" that will transform reproductive medicine.
However, Professor Angus Clarke, a clinical geneticist at Cardiff University, cautioned that using the test for broad exploratory screening could reveal genes of unknown significance, potentially causing significant anxiety for parents and leading to unnecessary medical surveillance for infants. He highlighted the difficulty parents might face when presented with potential answers without a specific condition being sought.